Abstract:Background: Intrahepatic Cholangiocarcinoma (iCCA) is a highly malignant tumor with limited treatment options that contributes largely to cancer-related deaths worldwide. Compared with traditional transcriptomic analysis, single-cell RNA sequencing (scRNA-seq) is emerging as a more advanced and popular tool for the in-depth exploration of cellular diversity and molecular complexity. As a next-generation proteasome inhibitor, MLN2238 presents better pharmacodynamics, pharmacokinetics, and therapeutic responses in various cancers. However, its effects and mechanisms of action in iCCA remain unknown.Methods: iCCA tumor heterogeneity was determined based on 4,239 qualified scRNA-seq data from 10 iCCA samples. The potential biological roles of proteasome-related genes in iCCA were investigated using a pseudo-trajectory reconstruction. The effect of MLN2238 on iCCA cell proliferation was estimated using the CCK-8, EdU, and clone formation assays. Flow cytometry was used to examine the effect of added MLN2238 on cell cycle and apoptosis levels. Autophagic flux was detected using AdPlus-mCherry-GFP-LC3B cells. ROS levels and mitochondrial membrane potential were determined using DCFH-DA probing and JC-1 staining. JNK activation and mitochondrial apoptosis were observed using western blotting and immunofluorescence microscopy, respectively. Finally, we used a tumor-bearing mouse model to validate its efficacy in vivo for iCCA treatment.Results: Proteasome-related genes were dysregulated in iCCA progression and expressed at higher levels in tumor tissues. MLN2238 suppressed cell proliferation, blocked the cell cycle in the G2/M phase, promoted apoptosis, and induced cytoprotective autophagy in iCCA cells. Furthermore, MLN2238 increased ROS levels and activated the JNK signaling pathway. Inhibition of ROS and JNK activation by NAC and SP600125 significantly reversed MLN2238-induced apoptosis. MLN2238 also suppressed the growth of iCCA tumors in vivo.Conclusion: Proteasome-related genes play pivotal roles in iCCA development. MLN2238, as a proteasome inhibitor, induces apoptosis in iCCA cells through ROS/JNK/mitochondrial signaling pathways, and hence, making MLN2238 a potential therapeutic choice for iCCA.

Data from The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

Synergistic inhibition of autophagy and neddylation pathways as a novel therapeutic approach for targeting liver cancer.

Inactivation of the Cullin (CUL)-RING E3 Ligase by the NEDD8-activating Enzyme Inhibitor MLN4924 Triggers Protective Autophagy in Cancer Cells

AKT Inhibitor MK-2206 Sensitizes Breast Cancer Cells to MLN4924, a First-in-class NEDD8-activating Enzyme (NAE) Inhibitor

Induction Of Protective Autophagy In Cancer Cells By Nae Inhibitor Mln4924

Targeting Cullin-RING Ligases by MLN4924 Induces Autophagy Via Modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR Axis.

Supplementary Figure 2 from the Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

Suppression of tumor angiogenesis by targeting the protein neddylation pathway.

Supplementary Figure 4 from the Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

Supplementary Figure 1 from The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

Targeting Neddylation Pathways to Inactivate Cullin-RING Ligases for Anticancer Therapy

MLN2238 exerts its anti-tumor effects <i>via</i> regulating ROS/JNK/mitochondrial signaling pathways in intrahepatic cholangiocarcinoma

Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells

Supplementary Figure 3 from the Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

The Nedd8-activating Enzyme Inhibitor MLN4924 (Tak-924/Pevonedistat) Induces Apoptosis Via C-Myc-noxa Axis in Head and Neck Squamous Cell Carcinoma.

Targeting Protein Neddylation with an NEDD8-activating Enzyme Inhibitor MLN4924 Induced Apoptosis or Senescence in Human Lymphoma Cells.

Inhibition of Neddylation Modification by MLN4924 Sensitizes Hepatocellular Carcinoma Cells to Sorafenib

Overactivated neddylation pathway as a therapeutic target in lung cancer

Induction of P21-Dependent Senescence by an NAE Inhibitor, MLN4924, As a Mechanism of Growth Suppression.

PD-L1 Induction Via the MEK-JNK-AP1 Axis by a Neddylation Inhibitor Promotes Cancer-Associated Immunosuppression

The NEDD8-activating enzyme inhibitor MLN4924 induces G2 arrest and apoptosis in T-cell acute lymphoblastic leukemia.